Comparison of Pulmonary Function Decline in Steroid-Treated and Steroid-Naive Patients with Duchenne Muscular Dystrophy.
Sawnani, H; Horn, PS; Wong, B; Darmahkasih, A; Rybalsky, I; Shellenbarger, KC; Tian, C; Rutter, MM; Simakajornboon, N; Amin, R; et al.
The Journal of Pediatrics.
2019;
210:194-200.e2.
White Matter Lesions Detected by Magnetic Resonance Imaging in Neonates and Children With Congenital Myotonic Dystrophy.
Peglar, LM; Nagaraj, UD; Tian, C; Venkatesan, C.
Pediatric Neurology.
2019;
96:64-69.
Consensus-based care recommendations for adults with myotonic dystrophy type 1.
Ashizawa, T; Gagnon, C; Groh, WJ; Gutmann, L; Johnson, NE; Meola, G; Moxley, R; Pandya, S; Rogers, MT; Simpson, E; et al.
Neurology: Clinical Practice.
2018;
8:507-520.
Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Wong, BL; Rybalsky, I; Shellenbarger, KC; Tian, C; McMahon, MA; Rutter, MM; Sawnani, H; Jefferies, JL.
The Journal of Pediatrics.
2017;
182:296-303.e1.
Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
Tian, C; Wong, BL; Hornung, L; Khoury, JC; Miller, L; Bange, J; Rybalsky, I; Rutter, MM.
Neuromuscular Disorders.
2016;
26:760-767.